Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) EBITDA (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of EBITDA data on record, last reported at -$7.2 million in Q4 2025.

  • For Q4 2025, EBITDA rose 36.97% year-over-year to -$7.2 million; the TTM value through Dec 2025 reached -$12.2 million, up 81.52%, while the annual FY2025 figure was -$12.2 million, 81.52% up from the prior year.
  • EBITDA reached -$7.2 million in Q4 2025 per VRCA's latest filing, down from $1.6 million in the prior quarter.
  • Across five years, EBITDA topped out at $1.6 million in Q3 2025 and bottomed at -$24.8 million in Q3 2023.
  • Average EBITDA over 5 years is -$10.2 million, with a median of -$9.9 million recorded in 2021.
  • Peak YoY movement for EBITDA: plummeted 21118.64% in 2023, then skyrocketed 109.93% in 2025.
  • A 5-year view of EBITDA shows it stood at -$9.6 million in 2021, then soared by 38.3% to -$5.9 million in 2022, then crashed by 316.97% to -$24.6 million in 2023, then soared by 53.64% to -$11.4 million in 2024, then skyrocketed by 36.97% to -$7.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$7.2 million in Q4 2025, $1.6 million in Q3 2025, and $1.5 million in Q2 2025.